o2h ventures operates the o2h human health EIS fund focused on early stage biotech therapeutics and AI opportunities.
Portfolio
4
companies
CardiaTec Biosciences
CardiaTec Biosciences applies artificial intelligence to multiomic data for cardiovascular drug discovery.
PhoreMost
PhoreMost develops targeted therapies for cancer and age related conditions.
PharmEnable
PharmEnable develops next-generation small molecule drugs for challenging disease targets using an artificial intelligence platform.
Qkine
Specialist manufacturer of proteins for stem cell and regenerative medicine applications
The pre-seed round was co-led by Laidlaw Scholars Ventures and APEX Ventures.
"Recent advances in artificial intelligence are generating novel ways to interpret multiomic data. I am excited to lead CardiaTec’s technology strategy to establish a new paradigm for understanding the pathophysiology of cardiovascular diseases."
The financing round was led by BGF with participation from new and existing backers to support clinical development.
"We are thrilled to include this exceptional group of investors in PhoreMost’s Series B funding round. We are grateful for the continued support of existing investors and are delighted to welcome BGF, alongside strategic investors XtalPi with whom we have a highly valued ongoing research collaboration, and Astellas Venture Management."
The oversubscribed round was led by Cambridge Enterprise and will fund the company's transition into drug development.
"We are pleased to welcome on board our new investors and appreciate their confidence in our business. Our aim is to replicate the specificity of biologics in the powerful and scalable form of a small molecule, to treat devastating diseases where there are currently no treatment options. We have proven the strength of our platform in tapping unexplored parts of the chemical universe to find novel and specific hits for currently undruggable targets, and are excited to now be able to invest in our own pipeline of drug discovery programmes, as well as to develop further strategic partnerships."
Parkwalk led the series A round with participation from life science investors and angels to fund international expansion and senior hires.
"There is a clear market need for high-quality protein reagents, especially for applications in stem cell biology and organoid research. Qkine has both a compelling technology to meet this need and a highly experienced management team to drive the growth of the business."
